TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03349047

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention group
Description: Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Description: The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
Study: NCT03466372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: biofeedback
Description: treadmill walking with biofeedback regarding propulsion and other gait parameters

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: biofeedback
Description: treadmill walking with biofeedback regarding propulsion and other gait parameters
Study: NCT05340595

Intervention type: OTHER
Group type: OTHER
Intervention: Orthodontic retainer bonding
Description: Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic retainer bonding
Description: Self-etch primer (Transbond XT Primer; 3M Unitek, California) was administered to the teeth's lingual surfaces.
Study: NCT01898130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01723943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive the What's Happening to the Woman I Love? booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo Helping Her Heal educational counseling program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo Helping Her Heal educational counseling program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychosocial support for caregiver
Description: Undergo Helping Her Heal educational counseling program
Study: NCT04673994

Intervention type: BEHAVIORAL
Intervention: Single, acute bout of high intensity interval exercise
Description: Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.

Intervention type: BEHAVIORAL
Intervention: Single, acute bout of high intensity interval exercise
Description: Individuals will perform a single bout of high intensity interval exercise on a seated recumbent stepper. Participants will perform the pattern of high intensity interval exercise by switching between 1-minute high intensity stepping followed by 1-minute light, active recovery stepping for a total of 10 minutes.
Study: NCT00243061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study: NCT02829814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet, 2.8 mg
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Study: NCT01710761

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same form factor and flavor as test lozenge but contains no active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplement with caffeine
Description: Lozenge consisting of beetroot and 75 mg caffeine
Study: NCT02930941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
Study: NCT04368910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine - artesunate
Description: Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.
Study: NCT04398134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-H2158
Description: 3 X 100 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic the ABI-H2158 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: 0.5 mg tablet for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir (ETV)
Description: 0.5 mg tablet for oral administration
Study: NCT04482790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional celluloid matrix technique in management of black triangle
Description: conventional restorative technique in management of black triangle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioclear cervical matrix with injection molding technique
Description: New restorative technique in management of black triangle restorative papilla regeneration
Study: NCT03802110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.
Description: The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
Study: NCT04505917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinoprostol
Description: 2 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
Study: NCT00469937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium carbonate
Description: Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
Study: NCT04505917

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: 2 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablet of placebo inserted by the study nurse 3 hours before IUD insertion
Study: NCT00469937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: cognitive assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
Study: NCT02135536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282
Study: NCT03812328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2
Description: I.V., single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SelK2
Description: I.V., single-dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: SC, QD for up to 10 ± 2 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: SC, QD for up to 10 ± 2 days
Study: NCT04292886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen and femoston
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C and femoston
Description: Vitamin C and femoston
Study: NCT03963830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE UP
Description: Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (\<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; \>250 pounds = 1800 kcal/d).
Study: NCT03041870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-fMRI scan
Description: fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of \[11C\]DASB bolus.
Study: NCT04181645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
Study: NCT03589703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Target ear points related to chronic low back pain (T-APA)
Description: Light touch using vaccaria seeds on specific points of the ear.
Study: NCT02621684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: International Physical Activity Prevalence Study Environmental Module
Description: -The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International Physical Activity Prevalence Study Environmental Module
Description: -The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
Study: NCT03589703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Target ear Points not related to chronic low back pain (NT-APA)
Description: Light touch using vaccaria seeds on different points of the ear (compared to the APA group).

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Educational Control Group (CG-2)
Description: No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
Study: NCT03837275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique
Description: Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closed maxillary sinus lift
Description: transdcrestal sinus lift and immediate implant placment
Study: NCT00103506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib (VELCADE)
Description: 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
Study: NCT02621684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Description: -4 item query of usual leisure time exercise habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Description: -4 item query of usual leisure time exercise habits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Description: -4 item query of usual leisure time exercise habits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire regarding behavior/lifestyle changes since diagnosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire regarding behavior/lifestyle changes since diagnosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire regarding behavior/lifestyle changes since diagnosis
Study: NCT00103506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (VELCADE)
Description: 1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride (DOXIL/CAELYX)
Description: mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Study: NCT02135536

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282
Description: NGM282
Study: NCT01000103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS
Description: Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations
Study: NCT04033536

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved Target Stereotacic Spine Radiosurgery
Description: Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
Study: NCT02621684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week Walking Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week Resistance Training Program
Study: NCT00972933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
Study: NCT03684239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G-CBT
Description: CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
Study: NCT01840059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Description: A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
Study: NCT04033536

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Elective Target Stereotacic Spine Radiosurgery
Description: Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
Study: NCT00923702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
Description: The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
Description: The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
Description: The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
Description: The participants received either one, two or three doses of the avaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18.
Study: NCT03925714

Intervention type: OTHER
Group type: OTHER
Intervention: life style
Description: life sryle control only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigetella salivata
Description: NS twice daily
Study: NCT03419871

Intervention type: OTHER
Intervention: Monitoring Sleep
Description: An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.

Intervention type: OTHER
Intervention: stress biomarkers
Description: Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress.
Study: NCT06368362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benign cognitive bias modification for interpretation
Description: Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benign cognitive bias modification for interpretation
Description: Benign cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as neutral or benign rather than pain-related.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pain-related cognitive bias modification for interpretation
Description: Pain-related cognitive Bias Modification for Interpretation (CBM-I) trains participants to interpret ambiguous information as pain-related.
Study: NCT01029821

Intervention type: DRUG
Group type: OTHER
Intervention: Low-Molecular-Weight Heparin
Description: Isolated Ankle Fracture Single planned operation
Study: NCT00422435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
Description: Paclitaxel-Eluting Coronary Stent
Study: NCT02999321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aspartame
Description: will be given 5mg aspartame or 15 mg aspartame

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aspartame
Description: will be given 5mg aspartame or 15 mg aspartame

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water
Description: control group